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After this treatment, tumor lysis syndrome and renal failure PBSCT should be examined for contaminating lymphoma cells whenever possible. developed, the incipient signs of which were already present before chemotherapy was initiated. Systemic
At the same time, the biological characteristics of the tumor cells at second relapse were clearly different from cytarabine was then given at an absolute dose of 360 mg followed by another course of VIP-E chemotherapy. Renal the prior presentations. This could have been an effect of clonal selection by prior chemotherapy and of a sponfailure was corrected, and another CR induced with no evidence of residual lymphoma or persistent marrow infiltaneous clonal evolution of the lymphoma to a higher degree of aggressiveness. Unfortunately, we have not been tration.
Consolidation salvage therapy now consisted of busulfan able to find histological or histochemical markers as a correlate for this clinical evolution. and cyclophosphamide (BU 4 mg/kg/day × 4, CY 60 mg/kg/day × 2). PBSCT was performed with the remaining However, the phenotype of the lymphoma at relapse (positive for CD5, CD10, CD19, CD20, CD71, HLA-DR; aliquot of PBSCs harvested prior to the first HDC. The leucapherisate utilized for salvage HDC and second PBSCT kappa+/lambda−) included a light-chain restriction that might not have been present at initial diagnosis. Therefore, showed no evidence of residual lymphoma cells by morphological examination, immunophenotyping and a combiwe cannot exclude that the changing characteristics of the tumor cells at relapse contributed to the success of the nation of both methods (for example, the malignant clone was CD10 positive while the leucapherisate was completely second salvage therapy. Indeed, the malignant clone at second relapse may have been even more chemosensitive CD10 negative).
Using the criteria proposed by the International Nonthan its predecessors. Naturally, further conclusions as to the relative value of BEAM or BU/CY HDC in the treatHodgkin's Lymphoma Prognostic Factors Project, 6 the patient had a number of relevant risk factors. At initial diagment of relapsed high-grade lymphomas can only be drawn from studies with large patient populations. nosis: elevated LDH, performance status Ͼ1; at first relapse Ann Arbor stage ϾII was added; and at second relapse all These observations may have implications for the prevention as well as for the management of lymphoma relapse three risk factors were again present. As the lymphoma remained chemosensitive, refractoriness was not an after HDC and autologous PBSCT. additional poor prognostic feature. Aggressive salvage therapy therefore was justified in our eyes in either relapse setting.
References The patient has since remained in CR for 27+ months.
